Last edition
News about
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Naprod Life Sciences Secures ANVISA GMP Renewal for Tarapur Facility
Naprod Life Sciences has received renewal of its Good Manufacturing Practice (GMP) certification from Brazil’s health regulator, ANVISA, for its Tarapur manufacturing facility in Maharashtra.
OneSource Reports INR 47 Crore Net Loss in Q3 FY26 as Revenue Falls 26 Percent
OneSource Specialty Pharma reported a weak performance in the third quarter of FY26, posting a net loss of INR 47 crore for the quarter ended December 31, 2025. The company’s revenue declined 26 percent year on year to INR 290 crore, largely due to delays in converting a key service agreement into a commercial supply contract.
Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.
Merck Ends Acquisition Talks With Revolution Medicines
Merck has ended discussions to acquire cancer drug developer Revolution Medicines after the two sides failed to agree on valuation, according to reports. The talks, which had been ongoing for several weeks, were discontinued as differences over pricing could not be resolved.
Eisai Submits EMA Application for Once-Monthly Maintenance Dosing of Alzheimer's Drug Lecanemab
BioArctic partner Eisai has filed a Marketing Authorisation Variation with the EMA seeking approval for a once-every-four-weeks IV maintenance dosing regimen for lecanemab in early Alzheimer’s disease.
Mair Therapeutics and Radboud University Partner to Advance Parkinson's Therapy
Mair Therapeutics has entered into a scientific collaboration with Radboud University to advance the development of TMEM175 agonists for Parkinson’s disease, with Dr Marijn Kuijpers’ laboratory at the Donders Centre for Neuroscience evaluating a portfolio of TMEM175-targeting compounds developed by the company.
FDA Clears Expanded Access Programme for StemCyte's RegeneCyte Therapy in Long covid Patients
The FDA has approved an Expanded Access programme for StemCyte’s RegeneCyte, enabling eligible Long covid patients to access the cord blood-based therapy amid ongoing clinical trials.
ACON Launches FDA-Cleared Flowflex Plus 4-in-1 Home Test for RSV, Flu and Covid, Including Infants
Acon Laboratories has launched the first FDA-cleared 4-in-1 home test detecting RSV, Flu A, Flu B and Covid-19, approved for adults and children as young as six months.
Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection
Sun Pharmaceutical has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management, paving the way for its entry into the fast-growing obesity treatment segment once the semaglutide patent expires in the country.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy